by email now.
“At our location in Lower Austria at the Technopol Wiener Neustadt, we can make wonderful use of synergies and benefit from the proximity to our cooperation partners.”
DI Alfred Zens, MBA, Managing Director, EBG MedAustron GmbH
The focus of current cancer research in Lower Austria is on improved diagnostics and more targeted and personalised therapy of serious diseases. The focus of current cancer research in Lower Austria is on improved diagnostics and more targeted and personalised therapy of serious diseases. For example, a new high-tech project will be developed in Wiener Neustadt from 2022 in cooperation between MedAustron – Centre for Ion Therapy and Research, the University of Applied Sciences Wiener Neustadt and the Lower Austrian Provincial Health Agency with the Provincial Hospital Wiener Neustadt. MedAustron is one of only six centres worldwide that have protons as well as carbon ions available.
With the start of production of the particle accelerator “Zyklotron” in 2025 for therapeutic radiation also radionuclides can be produced shortly before use.
These are needed for treatment or for sectional imaging examinations – such as the nuclear medicine examination PET (positron emission tomography), where tumours and metastases can be made visible.
Is your institution or company also active in the field of cancer research and treatment? Take advantage of the availability of optimal technical-scientific conditions and the possibilities of cooperation with the research institutions and high-tech companies located here. Establish your branch in Lower Austria, in the centre of Europe.
As the business agency of the Province of Lower Austria, we will support you free of charge and professionally in your settlement plans and find the optimal location for you. We use extensive networks to create the best possible conditions for your new location in Lower Austria.
Contact us without obligation right away by e-mail at email@example.com or by telephone directly to Mr. Slavisa Milanovic at +43 664 601 19721.
We look forward to hearing from you!